Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 198412, 6 pages
http://dx.doi.org/10.1155/2012/198412
Clinical Study

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

1Division of Medical Oncology C, Centro di Riferimento Oncologico, 33081 Aviano, Italy
2Epidemiology Unit, Centro di Riferimento Oncologico, 33081 Aviano, Italy
3Clinical Trial Office, Centro di Riferimento Oncologico, 33081 Aviano, Italy
4Pharmacy Unit, Centro di Riferimento Oncologico, 33081, Aviano, Italy

Received 26 October 2011; Revised 5 January 2012; Accepted 20 January 2012

Academic Editor: Bruno Vincenzi

Copyright © 2012 Vincenzo Di Lauro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 182–191, 1987. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Paik, R. Hazan, E. R. Fisher et al., “Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer,” Journal of Clinical Oncology, vol. 8, no. 1, pp. 103–112, 1990. View at Google Scholar · View at Scopus
  3. S. Dawood, K. Broglio, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano, “Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Baselga, D. Tripathy, J. Mendelsohn et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 737–744, 1996. View at Google Scholar
  6. M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2639–2648, 1999. View at Google Scholar · View at Scopus
  7. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon, “Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 10, pp. 739–749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Di Lauro, A. Murrone, E. Bidoli, M. D. Magri, D. Crivellari, and A. Veronesi, “Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience,” Tumori, vol. 94, no. 4, pp. 464–468, 2008. View at Google Scholar · View at Scopus
  10. H. J. Burstein, I. Kuter, S. M. Campos et al., “Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 19, no. 10, pp. 2722–2730, 2001. View at Google Scholar · View at Scopus
  11. M. Jahanzeb, J. E. Mortimer, F. Yunus et al., “Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer,” The Oncologist, vol. 7, no. 5, pp. 410–417, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Chan, “A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer,” Annals of Oncology, vol. 18, no. 7, pp. 1152–1158, 2007. View at Publisher · View at Google Scholar
  13. A. Chan, L. Petruzelka, M. Untch et al., “Long term survival of vinorelbine and trastuzumab as first line therapy for HER2-positive metastatic breast cancer patients,” Journal of Clinical Oncology, vol. 23, supplement 16, abstract 587, 2005. View at Google Scholar
  14. M. De Wit, K. Becker, C. Thomssen et al., “Vinorelbine and trastuzumab as first line therapy in patients with Her2-positive metastatic breast cancer: interim analysis of a prospective open-label, multicentre phase II trial,” Annals of Oncology, vol. 3, supplement 15, abstract 138P, 2004. View at Google Scholar
  15. H. J. Burstein, L. N. Harris, P. K. Marcom et al., “Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2889–2895, 2003. View at Publisher · View at Google Scholar
  16. P. Papaldo, A. Fabi, G. Ferretti et al., “A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease,” Annals of Oncology, vol. 17, no. 4, pp. 630–636, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. l. Bayo-Calero, J. l. Mayordomo-Camara, and P. Sanchez-Rovira, “A multicenter study with trastuzumab and vinorelbine as first and second line treatment in patients with HER2 positive metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 88, supplement 1, abstract 5096, pp. 207–208, 2004. View at Google Scholar
  18. Y. Suzuki, Y. Tokuda, Y. Saito, M. Ohta, and T. Tajima, “Combination of trastuzumab and vinorelbine in metastatic breast cancer,” Japanese Journal of Clinical Oncology, vol. 33, no. 10, pp. 514–517, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. García-Sáenz, M. Martín, J. Puente et al., “Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer,” Clinical Breast Cancer, vol. 6, no. 4, pp. 325–329, 2005. View at Google Scholar · View at Scopus
  20. H. J. Burstein, A. Keshaviah, A. D. Baron et al., “Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study,” Cancer, vol. 110, no. 5, pp. 965–972, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Andersson, E. Lidbrink, K. Bjerre et al., “Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study,” Journal of Clinical Oncology, vol. 29, no. 3, pp. 264–271, 2011. View at Publisher · View at Google Scholar
  22. P. A. Bunn, B. Helfrich, A. F. Soriano et al., “Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents,” Clinical Cancer Research, vol. 7, no. 10, pp. 3239–3250, 2001. View at Google Scholar · View at Scopus
  23. J. A. O'Shaughnessy, S. Vukelja, T. Marsland, G. Kimmel, S. Ratnam, and J. E. Pippen, “Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer,” Clinical Breast Cancer, vol. 5, no. 2, pp. 142–147, 2004. View at Google Scholar · View at Scopus
  24. A. B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, “Reporting results of cancer treatment,” Cancer, vol. 47, no. 1, pp. 207–214, 1981. View at Google Scholar · View at Scopus
  25. NCI-CTCAE grade v3.0: National Cancer Institute Common Terminology Criteria for Adverse Events.
  26. M. Jahanzeb, “Trastuzumab-based combinations in metastatic breast cancer: how to make a choice,” Clinical Breast Cancer, vol. 4, no. 1, pp. 28–38, 2003. View at Google Scholar · View at Scopus
  27. D. A. Yardley, H. A. Burris, S. Hanson et al., “Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer,” Clinical Breast Cancer, vol. 9, no. 3, pp. 178–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Von Minckwitz, A. du Bois, M. Schmidt et al., “Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1999–2006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, pp. 2733–2743, 2006. View at Google Scholar
  30. H. A. Burris III, H. S. Rugo, S. J. Vukelja et al., “Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 398–405, 2011. View at Publisher · View at Google Scholar
  31. J. Baselga, K. A. Gelmon, S. Verma et al., “Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1138–1144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. H. J. Burstein, Y. Sun, L. Y. Dirix et al., “Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1301–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus